NEUROCRINE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEUROCRINE, and when can generic versions of NEUROCRINE drugs launch?
NEUROCRINE has two approved drugs.
There are thirty-one US patents protecting NEUROCRINE drugs.
There are three hundred and one patent family members on NEUROCRINE drugs in forty-three countries and nineteen supplementary protection certificates in sixteen countries.
Drugs and US Patents for NEUROCRINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | 10,844,058 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | 8,357,697 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-001 | Apr 24, 2020 | RX | Yes | No | 8,907,099 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-001 | Apr 24, 2020 | RX | Yes | No | 10,583,130 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | 11,439,629 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEUROCRINE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 2124947 | ⤷ Try a Trial |
Mexico | 2020003421 | ⤷ Try a Trial |
Japan | 2021183641 | ⤷ Try a Trial |
Canada | 2678391 | ⤷ Try a Trial |
Australia | 2022203201 | ⤷ Try a Trial |
Israel | 273300 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NEUROCRINE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1907382 | SPC/GB16/065 | United Kingdom | ⤷ Try a Trial | CORRECTION OF GRANT INFORMATION ON SUPPLEMENTARY PROTECTION CERTIFICATE APPLICATIONSAPPLICANT: BIAL-PORTELA & CA, S.A.A AVENIDA DA SIDERURGIA, NACIONAL, 4745-457 S.MAMEDE DO CORONADO, PORTUGALPRODUCT: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREO FPRODUCT TYPE: MEDICINAL AUTHORISED: UK EU/1/15/1066/001/010 28 JUNE 2016 AUTHORISED EXTENSION: PATENT NO: EP1907382 TITLE: NITROCATECHOL DERIVATIVES AS COMT INHIBITORS SPC NO: SPC/GB16/065DATE GRANTED: 20 NOVEMBER 2020 MAXIMUM PERIOD EXPIRES ON: 27 JUNE 2031*CORRECTION OF GRANT DETAILS IN JOURNAL NUMBER 6865 DATED 16 DECEMBER 2020 TO INCLUDE MAXIMUM EXPIRY DETAILS AND UPDATED AUTHORISATION DETAILS. |
1907382 | CR 2016 00061 | Denmark | ⤷ Try a Trial | PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628 |
1907382 | 93327 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: OPICAPONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/15/1066 - ONGENTYS - OPICAPONE |
1907382 | CA 2016 00061 | Denmark | ⤷ Try a Trial | PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628 |
1907382 | PA2016036,C1907382 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: OPIKAPONAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/15/1066 20160624 |
1907382 | 132016000123029 | Italy | ⤷ Try a Trial | PRODUCT NAME: OPICAPONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ONGENTYS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1066, 20160628 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.